NeuroPace, Inc. Stock News

NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2021 Results - Earnings Call Transcript

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.

NeuroPace's (NPCE) CEO Mike Favet on Q1 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, t

MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of p

NeuroPace aims to improve the lives of epilepsy patients. The company has a savvy remote monitoring system which provides real-time action.

MOUNTAIN VIEW, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of p

There have been quite a few appealing Initial Public Offerings (IPOs) available on the market so far this year. Here are some upcoming IPOs that investors should be watching out for.